Page 1

MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statement of Comprehensive Income ( unaudited ) Exhibit 99.1 Six months ended June 30 , 2021 Revenue Cost of revenue Research and development expenses Administrative expenses Operating loss Finance income Finance costs Changes in the fair value of financial instruments Loss on disposal of intangible assets Net foreign exchange loss Profit / ( loss ) before tax Taxation Profit / ( loss ) for the period , attributable to equity holders of the parent Basic profit / ( loss ) per share for the period ( in £ ) Notes 3 £ ' 000 Six months ended June 30 , 2020 £ ' 000 36,464 ( 18,137 ) ( 9,858 ) ( 8,479 ) ( 8,673 ) ( 8,212 ) ( 204 ) ( 16,691 ) 1 39 4 ( 1,987 ) ( 2,924 ) 4 14,363 ( 94,704 ) ( 11,302 ) ( 1,269 ) ( 519 ) 10,904 ( 126,101 ) 1,184 1,482 12,088 ( 124,619 ) 5 0.02 ( 1.05 ) Diluted loss per share for the period ( in £ ) 5 0.00 ( 1.05 ) Fair value changes on investments held at fair value through OCI 3 Currency translation of foreign operations ( 26 ) 1,324 Total comprehensive profit / ( loss ) for the period , attributable to equity holders of the parent 12,062 ( 123,292 ) The accompanying notes form an integral part of these unaudited condensed consolidated financial statements .